Karyopharm Therapeutics Inc [KPTI] stock prices are up 5.65% to $1.31 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KPTI shares have gain 3.15% over the last week, with a monthly amount glided 49.59%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024. In a post published today on Yahoo Finance, — Conference Call Scheduled for Thursday, February 29, 2024, at 8:00 a.m. ET –.
From an analyst’s perspective:
Karyopharm Therapeutics Inc [NASDAQ: KPTI] stock has seen the most recent analyst activity on January 19, 2023, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $8. Previously, RBC Capital Mkts upgraded its rating to Outperform on November 04, 2022, and elevated its price target to $10. On February 09, 2022, upgrade upgraded it’s rating to Neutral but maintained its price target of $8 on the stock. SVB Leerink downgraded its rating to a Mkt Perform but $6 remained the price target by the analyst firm on August 06, 2021. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 06, 2021, and downed its price target to $8. In a note dated August 06, 2021, JP Morgan downgraded an Neutral rating on this stock.
The stock price of Karyopharm Therapeutics Inc [KPTI] has been fluctuating between $0.62 and $4.87 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Karyopharm Therapeutics Inc [NASDAQ: KPTI] shares were valued at $1.31 at the most recent close of the market. An investor can expect a potential return of 587.02% based on the average KPTI price forecast.
Analyzing the KPTI fundamentals
The Karyopharm Therapeutics Inc [NASDAQ:KPTI] reported sales of 145.87M for trailing twelve months, representing a drop of -0.38%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2300 points at the first support level, and at 1.1500 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3800, and for the 2nd resistance point, it is at 1.4500.
Karyopharm Therapeutics Inc [KPTI] reported earnings per share of -$0.3 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.28/share, meaning a difference of -$0.02 and a surprise factor of -7.10%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.29 per share as compared to estimates of -$0.34 per share, a difference of $0.05 representing a surprise of 14.70%.
Ratios To Look Out For
It’s worth pointing out that Karyopharm Therapeutics Inc [NASDAQ:KPTI]’s Current Ratio is 4.24. In addition, the Quick Ratio stands at 4.19 and the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 1.03.
Transactions by insiders
Recent insider trading involved Poulton Stuart, EVP, Chief Development Officer, that happened on Feb 15 when 5847.0 shares were sold. EVP, CFO & Treasurer, Mason Michael completed a deal on Feb 06 to sell 4205.0 shares. Meanwhile, President and CEO Paulson Richard A. sold 4012.0 shares on Feb 06.
